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Abstract
Background: To evaluate the role of flow cytometric immunophenotyping (FCI) in diagnosis and
characterization of lymphoma tissue specimens from Egyptian patients.
Methods: FCI using 2 and 3 color staining approaches, was performed on 50 fresh lymph nodes
specimen from Cairo NCI patients with suspected lymphoma presenting with either localized or
generalized lymphadenopathy.
FCI results were correlated with histopathologic as well as immunophenotypic[by
immunohistochemistry (IHC)] findings.
Results: By FCI, cases were diagnosed as follows: 9(18%) reactive hyperplasia (RH), 32(64%) B-
cell non-Hodgkin's lymphoma (B-NHL) [24 diffuse large (DLBCL), 2 follicular, 3 small lymphocytic,
2 mantle cell lymphoma and a case of T cell rich B cell lymphoma], 3 (6%) T cell NHL [2 peripheral
T cell lymphoma and a case of anaplastic large cell lymphoma], 2(4%) Hodgkin's lymphoma (HL)
while 4 (8%) were non-lymphomatous tumors (NLT). Light chain restriction (LCR) was detected
in the 32 FCI diagnosed B-NHL. The overall concordance between FCI versus histopathology and
IHC was 88%. The sensitivity and specificity of FCI in diagnosis of NHL was 94.9% and 100%
respectively; in HL they were 40% and 100% respectively and in NLT, both sensitivity and specificity
were 100% while for RH were 100% and 89.1% respectively.
Conclusion: FCI is a sensitive and specific method in diagnosis and classification of NHL as well
as in detection of monoclonality. False negative results could be due to the presence of
heterogeneous populations of lymphocytes in special types of lymphoma.
Introduction
Lymphoma represents one of the major health problems
allover the world. It is a common malignancy affecting
both children and adults and is continuing to increase
rapidly. In the Middle East, non-Hodgkin's lymphoma
(NHL) has a high incidence contributing to 7% of total
cancer [1] as compared to 4% in USA [2].
In Egypt, lymphoma represented 11.66% of all diagnosed
cancer cases at the NCI-Cairo University during the period
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2003–2004 according to the Cancer Pathology Registry,
with non-Hodgkin's lymphoma constituting 76.5% of
these cases. The B-phenotype comprised 81.1% while T-
phenotype represented 9.8% while 9.1% of the cases were
non-specified [3].
The advent of immunophenotyping of samples from
patients with lymphoproliferative disorders has added
much to proper diagnosis and classification and better
understanding of the pathogenetic mechanisms underly-
ing the development of these disorders [4]. In the context
of lymphoma diagnosis, immunohistochemistry (IHC)
has the advantage that the cells of interest are identified
morphologically and it is applicable retrospectively to
fixed tissues, though fixation might lead to loss of some
cells and/or cellular antigenicity [5]. However, only a sin-
gle marker is routinely used on tissue sections, which per-
mits examination of about 100 cells only. Moreover, there
is a reported difficulty in demonstrating immunoglobulin
light chains [6].
On the contrary, flow cytometry (FCM) allows a more pre-
cise definition of individual cell types since the cells of
interest are identified by a combination of physical char-
acteristics and the use of multiple antibodies directly con-
jugated with different fluorochromes. It also has the
ability to assess monoclonality through detection of
immunoglobulin light chain expression and the results
can be available within few hours after receiving the spec-
imen [7-9].
In addition, flow cytometric immunophenotyping (FCI)
has become a widely used laboratory procedure for diag-
nosis and sub-typing of lymphoma. It is an objective and
quantitative diagnostic tool that allows quick multipara-
metric analysis of a very large number of cells (20.000–
50.000 cells per sample) which could be obtained from
small tissue sample (0.1 cm3 or even smaller). Meanwhile,
analysis of such small samples is facilitated by applying
dual & triple markers that permit in a single experiment,
the detection of expression of combination of 2 or 3 anti-
gens respectively on the same cell [10,11]
Several studies have supported the usefulness of FCI in
diagnosing lymphoma in fine needle aspiration (FNA)
samples as well as in staging and follow up of cases [12-
14].
However, only few reports are available regarding the role
of FCM in tissue diagnosis and typing of lymphoma.
Morse et al. [15] reported that 9 out of 16 cases (56%)
were diagnosed by FCI alone as lymphoma or carcinoma
and 4 (25%) were consistent with a final diagnosis of nor-
mal or reactive hyperplasia whereas, 3 cases only had his-
tologic evidence of malignancy on biopsies that escaped
detection by FCM. Moreover, Dunphy, [16] reported that
FCI data contributed significantly to, or was consistent
with the final tissue diagnosis in 94% of a large series
including 373 cases. Furthermore, Martinez et al. [17]
reported that FCI diagnosed 218 cases of NHL out of 250
cases with negative predictive value 0.52 and positive pre-
dictive value 1.
In 2000 mayall et al.[18], Dunphy [19] reported that FCI
in combination with touch imprint cytomorphology was
useful in excluding diagnosis of lymphoma and non lym-
phomatous tumors & showed 100% concordance with
histopathologic results.
Regarding Ig light chain detection by FCM, Leers et al. [20]
estimated the clonality of lymphoproliferative disorders
by FCI & IHC. They pointed out a major drawback of
immunohistochemical detection of monoclonality in B-
cell lymphoproliferative disorders which was the lack of
contrast between surface-immunoglobulin staining and
extracellular immunoglobulin staining. Monoclonality
was established in 9 out of 10 NHL cases by FCI while
only 6 of 9 cases were conclusive by IHC.
The present study was conducted to assess the diagnostic
role of FCM for immunophenotyping of lymphoma on
freshly excised tissue biopsies by comparing the results of
FCI to routine histopathology and immunohistochemis-
try.
Methods
The study included 57 freshly excised lymph node speci-
mens obtained from patients who attended to the
National Cancer Institute clinics, Cairo University during
the period 2003–2006 complaining of localized or gener-
alized lymphadenopathy. The mean age of patients was
47.7 (range 5–72 years).
Specimens were immediately suspended in sterile chilled
RPMI-1640 tissue culture medium. Each specimen was
divided into three parts, the first part was used for the
preparation of touch imprints stained by modified PAP to
assess the presence of malignant lymphoma cells and
facilitate diagnosis, the second was used to prepare single
cell suspension by mechanical dispersion for FCI, and the
third was put in 10% neutral buffered formalin, embed-
ded in paraffin and processed routinely for histologic
diagnosis and immunohistochemistry for lymphoma sub-
typing.
Flow cytometric immunophenotyping (FCI)
Immunohistochemistry (IHC)
FCI results were correlated with histopathologic / immu-
nohistochemical  immunophenotyping results  per-
formed on paraffin-embedded material according toDiagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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standard protocols using the following antibodies (all
from Dako Ltd., Cambridge, UK): CD45 (LCA, T29),
CD20 (L-26), CD79acy (HM57), CD3 (PC3), CD45RO
(UCHL1), CD5 (CD5/45/F6), CD4 (OPD4), CD8 (C8),
CD10 (SS2/36), CD56 (NK1), CD15, CD30, ALK-1.
Preparation of a single cell suspension
Cells from affected nodes were dispersed by squeezing the
tissues against nylon or metal mesh (pore size 50–70 μm)
into a glass beaker. Tissues were always kept wet by adding
sterile phosphate buffered saline solutions (PBS) or serum
to maintain cell viability. The suspension was then centri-
fuged 4–5 min at 1200–1400 rpm, the supernatant was
discarded and the cell pellet was resuspended in 2 ml PBS.
Part of the suspension was used for assessing cell viability
by staining with trypan blue and cell counting [14]. The
percentage viability was calculated, the required total
number is around 106/ml and the optimum acceptable
percent of viable cells is about 80% [21].
The rest of the suspension was subjected to staining for
FCI analysis. Cell surface antigen staining was performed
using specific directly conjugated fluorochrome-labeled
monoclonal antibodies which were assembled in panels
according to case requirement. The monoclonal antibod-
ies used were CD45, CD45RO, CD 20, CD19, CD3,
CD10, CD5, CD23, CD30, CD15, bcl-2, anti-κ, anti-λ,
CD4 and CD8 [6].
Antibody panels design
Isotype control IgG1-FITC/IgG2a-PE was used at the start
of each run. This was followed by staining with the screen-
ing triple marker; CD3-FITC/CD19-PE/CD45-PerCP. Fur-
ther analysis with the appropriate antibodies was
performed on the remaining of the sample based on the
initial results of both touch imprints and the screening tri-
ple marker. The markers used in this study (All from BD
Bioscience, USA) were: 1) The dual markers (CD5-FITC/
CD19-PE; Anti kappa-FITC/CD19-PE; Anti lambda-FITC/
CD19-PE; CD4-FITC/CD8-PE), and 2) The single markers
[CD20-FITC; CD10-FITC; CD45RO-PE; CD23-PE; CD30-
FITC; CD15-FITC; Anti-BCL2-FITC].
FCM quality control including alignment, calibration,
and color compensation was performed before sample
acquisition according to manufacture's instructional man-
ual.
Staining for FCI analysis
Staining was performed according to the manufacturer's
instructions (Becton Dickinson, Bioscience, USA). Briefly,
20 μl of each of the used monoclonal antibodies were
added to 100 μl of the cell suspension in separate tubes
and mixed by vortexing. This was followed by 30 min
incubation at room temperature (RT) in the dark, washed
twice in 2 ml of PBS and centrifugation for 5 min at 300 ×
g. Then 0.5 ml of 1% paraformaldehyde was added for fix-
ation and samples were acquired on the FCM after 30 min
[22].
Acquisition
Acquisition and analysis of stained suspension was per-
formed by FACScan flow cytometer (Becton Dickinson,
USA) acquiring at least 20.000 – 30.000 cells at a high rate
of 400–500 cells/second for each marker. Negative iso-
type control was run first to identify the position of the
negative and the positive populations. At least two plots
were drawn during the acquisition of each tube; one of
them displayed forward scatter (FSc) on X axis versus side
scatter (SSc) on Y axis to identify the size and granularity
of cells and to exclude debris and dead cells. The second
plot displayed the antibody marker on X axis versus FSc or
the other marker in case of dual markers on Y axis.
Data storage
Data was stored in the list-mode where the raw data for
each parameter on every analyzed cell were sequentially
stored in a list to allow reanalysis at any time including
redrawing gates, different population gating and new his-
togram drawing.
Sample analysis
Analysis of sample tubes was performed as follows: setting
cursors for differentiating positive and negative popula-
tions (Isotype control plot analysis) so that ≥ 98% of the
cells are negative. The tube containing CD45 (gating rea-
gent) was analyzed first to set a gate around lymphocyte
clusters using FSc and SSc patterns and fluorescence stain-
ing based on low FSc and SSc patterns and bright stain of
lymphocytes with CD45.
Light-scattering patterns were examined on each sample
tube and the remaining sample tubes were analyzed with
the cursors previously set based on the isotype control.
The data was reported as a percentage of the total lym-
phocytes and/or percentage of gated population. Absolute
numbers of positive and negative populations were also
reported.
Interpretation of data
The Size of cells was defined depending on FSc as: small
(FSc 200–400), medium (FSc 400–600) or large (FSc >
600) [21]. The fluorescence intensity was determined by
using a log scale of dot plot as follows: the population
which lies in region 10°-101 was considered negative,
region 101-102 was considered weak, region 102-103 was
considered moderate and region > 103 was considered
strong.
Detection of B-cell monoclonality
This was determined by overlay of histograms of both
anti-kappa and anti-lambda and measuring the differenceDiagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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between them using the Cell Quest software of the
machine. Light chain restriction (LCR) was considered
when κ/λ was < 0.5 or κ/λ was > 2.5 or if there is absence
of both κ & λ expression by tumor cells [19]. A negative
(isotype) reagent control was used with each specimen to
determine non-specific binding of the mouse monoclonal
antibody to the cells and to allow setting of markers for
distinguishing fluorescence-negative and fluorescence-
positive cell populations. The marker set on the negative
control plot was copied on each analyzed plot of dual
markers plots, so dividing it into 4 quadrants.
Analysis of the population in each quadrant was as fol-
lows: the lower left quadrant; double negative to both
markers, the lower right quadrant; positive for X axis
marker only, the upper left quadrant; positive for Y axis
marker only, and the upper right quadrant; positive to
both markers.
Statistical methods
Sensitivity and specificity of FCI as compared to his-
topathologic findings were calculated. Sensitivity is
defined as the probability of a positive test among
patients with disease. Specificity is the probability of a
negative test among patients without disease. The positive
predictive value (PPV) and the negative predictive value
(NPV) were also measured [23].
Results
Out of the 57 biopsies received, 50 were evaluated by both
FCM and IHC and 7 were not suitable for evaluation by
FCM due to reduced viability of cells below 85%. Thus
only these 50 cases were used in all statistical evaluation
& correlation of results.
The results of touch imprint
The stained touch imprints were evaluated as regards their
contribution to the FCI data and their role in facilitating
the diagnosis of cases. The cases were divided into 4
groups:  1)  7 cases (14%) showed small mature lym-
phocytes, suggestive of reactive hyperplasia (RH); 2) 37
cases (74%) showed variable features suggestive of NHL
of which, 26 (52%) showed large atypical lymphoid cells
with vesicular nuclei and prominent nucleoli associated
with atypical small to medium sized cells, 8 (16%)
revealed atypical small lymphoid cells and 3 (6%)
revealed atypical lymphocytes of varying size with irregu-
lar nuclear membranes, necrotic debris and multinucle-
ated cells; 3) Two cases (4%) revealed few large atypical
mononuclear cells and large bi-nucleated cells with prom-
inent nucleoli in a background of small lymphocytes sug-
gestive of Hodgkin's lymphoma (HL) and 4) 4 cases (8%)
showed non-lymphomatous malignant cells with scat-
tered or few lymphocytes, suggestive of non lymphoma-
tous or metastatic tumor (MT) (Table 1).
Flow cytometric (FCI) findings
Positive reaction of cells to monoclonal antibodies was
detected as fluorescent dots in the dot plot quadrants. The
distribution of dots differed depending on the number of
markers used and the status of positivity to each marker.
The diagnostic distribution of the 50 specimens according
to FCI was as follows: 9 cases (18%) were diagnosed as
RH, 32 cases (64%) were B-cell NHL, 3 cases (6%) were T-
cell NHL, 2 cases (4%) were HL and 4 cases (8%) were
diagnosed as non-lymphomatous (NLT) or metastatic
tumors (MT) (Table 1).
Within the group of B cell NHL (32 cases), 24 cases (75%)
were diffuse large B-cell lymphoma (DLBCL) showing
positive reaction to CD45, CD20, CD19 and large FSc
Sensitivity =
× Number of true positive cases 1
Number of tru
00
e e positive cases False negative cases +
Specificity =
× Number of true nagative cases 1
Number of tru
00
e e negative cases False positive cases +
Table 1: Correlation between touch imprints, flow cytometric immunophenotyping, routine histology and immunohistochemical 
findings.
Group Touch imprints No. (%) FCI No. (%) Histopathology & Immunohistochemistry No. (%)
RH 7 (14) 9 (18) 4 (8)
NHL 37 (74) 35 (70) 37 (74)
B-cell 32 (64) 34 (68)
T-cell 3 (6) 3 (6)
HL 2 (4) 2 (4) 5 (10)
MT 4 (8) 4 (8) 4 (8)
Total 50 (100) 50 (100) 50 (100)Diagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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(Fig. 1), 2 cases (6.25%) were follicular lymphoma (FL)
showing positive reaction to CD45, CD20, CD19, CD10,
anti-BCL-2 and small to medium FSc. Three cases (9.4%)
were small lymphocytic lymphoma (SLL) showing posi-
tive reaction to CD45, CD19, CD5, CD23 and small FSc,
2 cases (6.25%) were mantle cell lymphoma (MCL) show-
ing positive reaction to CD45, CD19, CD5, negative reac-
tion to CD23 and small FSc (Fig. 2), and a single case
(3.12%) was diagnosed as T-cell rich B-cell lymphoma
(TCRBCL) showing numerous T-cells which were
CD45RO+ve, CD3+ve with small FSc. The less common
(A) Touch imprint of DLBCL case showing large atypical lymphoid cells with vesicular nuclei and prominent nucleoli associated  with atypical small to medium sized cells (modified PAP, 400×), (B): DLBCL case showing diffuse infiltration by large atypical  lymphoid cells with vesicular nuclei and prominent nucleoli Figure 1
(A) Touch imprint of DLBCL case showing large atypical lymphoid cells with vesicular nuclei and prominent 
nucleoli associated with atypical small to medium sized cells (modified PAP, 400×), (B): DLBCL case showing 
diffuse infiltration by large atypical lymphoid cells with vesicular nuclei and prominent nucleoli. (H & E, 400×), 
(C): The same case showing positive reaction to CD 20 (400 ×), (D): FCM dot plots of a case of DLBCL showing (i) Large FSc, 
(ii) Negative isotype control (iii) Atypical large population showing positive reaction to CD45, CD 19, (iv) CD20 positive cells 
show large FSc (v&vi) Small population of CD 3 positive cells, (vii&viii) Absence of light chain expression by B-cells (LCR)
(B)    (A) 
(C )   
(D) 
 
(a)  (b)
(c)   (d)
(e) (f)
(g)   (h)Diagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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MCL case showing (A): Diffuse infiltration by monotonous atypical small lymphoid cells with dark nuclei and inconspicuous  nucleoli (H & E, 400 ×), (B): Positive reaction to CD 20 (400×), (C): Positive reaction to CD 5(400×), (D): Negative reaction to  CD23 (400×), (E): FCM dot plots of a case of MCL showing (i) Small FSc, (ii) Negative isotype control (iii, iv, v) Triple marker  showing atypical population showing positive reaction to CD45, CD 19, negative reaction to CD 3 (vi) B-cells show positive  reaction toCD 5, CD19 (vii) Negative reaction toCD 23 (viii) Monoclonality for λ light chain (ix) Overlapping histogram show- ing B-cell monoclonality expressing λ light chain (arrow) Figure 2
MCL case showing (A): Diffuse infiltration by monotonous atypical small lymphoid cells with dark nuclei and 
inconspicuous nucleoli (H & E, 400 ×), (B): Positive reaction to CD 20 (400×), (C): Positive reaction to CD 
5(400×), (D): Negative reaction to CD23 (400×), (E): FCM dot plots of a case of MCL showing (i) Small FSc, (ii) 
Negative isotype control (iii, iv, v) Triple marker showing atypical population showing positive reaction to 
CD45, CD 19, negative reaction to CD 3 (vi) B-cells show positive reaction toCD 5, CD19 (vii) Negative reac-
tion toCD 23 (viii) Monoclonality for λ light chain (ix) Overlapping histogram showing B-cell monoclonality 
expressing λ light chain (arrow).
(A)    (B)   
(C )    (D)   
(E) 
 
(a) (b
)
(c) (d
)
(e)  
(f) (g)  
(h)
(i)  Diagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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B-cells in this case were CD20+ve and CD19+ve. The B-
cells demonstrated large FSc and light-chain restriction.
The 3 cases which were diagnosed as T-cell NHL were fur-
ther subdivided into 2 cases (66.7%) of peripheral T-cell
lymphoma (PTCL) showing positive reaction to CD45,
CD3, CD45RO and a predominance of CD4+ve cells and
a single case (33.3%) of anaplastic large T-cell lymphoma
(ALTCL) with positive CD45, CD3, CD45RO and CD30
(Fig 3).
Light chain restriction (LCR) was detected in the 32 FCI-
diagnosed B-cell lymphoma cases, where the ratio of κ/λ
determined by FCM ranged from 0.14 to 15.67. Two out
of these 32 cases (6.25%) showed absence of both κ & λ
expression. A total of20 cases (62.5%) revealed mono-
clonality of κ-light chain with a mean of 5.73. The remain-
ing 10 cases (31.25%) showed monoclonal expression of
λ-light chain with a mean of 0.36. On the other hand, the
κ/λ in the 9 RH cases ranged from 0.57 to 1.09 with a
mean of 0.91 and they were all polyclonal.
Histopathologic data
The frequency distribution of the 50 cases evaluated by
histopathology/IHC was as follows: 4 cases (8%) were
diagnosed as RH, 34 (68%) were B-cell NHL, 3 (6%) were
T-cell NHL and 5 (10%) were HL. However, 4 cases (8%)
were confirmed as metastatic duct carcinoma of breast ori-
gin (Table 1). Accordingly, NHL represented 88.1% of the
diagnosed malignant lymphoma cases and HL repre-
sented 11.9% only with a ratio of 7.4: 1.
As regards to sub-typing by IHC of the 34 cases of B-cell
NHL: 23 cases (67.65%) were DLBCL, 3 (8.82%) were FL,
2 (5.88%) were MCL, 3 (8.82%) were SLL and 3 cases
(8.82%) were diagnosed as TCRBCL. On the other hand,
the 3 cases diagnosed as T-cell NHL by IHC were subdi-
vided into one case (33.3%) of PTCL and 2 cases (66.7%)
were ALCL.
Light chain expression by B-cell NHL cases was not evalu-
ated by immunohistochemistry, hence, it was not
reported in patients' records.
The correlations between FCI, histopathology and IHC
Seven groups were identified in the present study accord-
ing to the data obtained from FCI, histopathology/IHC:
A) 4 cases were diagnosed as RH by FCI and were morpho-
logically benign by histopathology; of which 3 were
proved to be follicular hyperplasia and one case was diag-
nosed as sinus histiocytosis, B) 2 cases were diagnosed as
RH by FCI but they were categorized as NHL by histopa-
thology/IHC (both cases proved to be TCRBCL), C)  3
cases were diagnosed as RH by FCI and were proved to be
HL by histopathology/IHC, D) 4 cases showed NLT by
FCI and were diagnosed as metastatic tumors by histopa-
thology/IHC, E) 32 cases were accurately diagnosed as B-
cell NHL lymphoma by both FCI and histopathology/
IHC, F) 3 cases were clearly defined as T-cell NHL lym-
phoma by both FCI as well as histopathology/IHC, and
G) 2 cases were diagnosed as HL by both FCI and histopa-
thology/IHC.
The overall concordance between FCI and histopathol-
ogy/IHC was 88% (44/50 cases; Table 2 & Fig 4).
Correlation between the diagnosis of B-cell NHL and T-
cell NHL subtypes by FCI and IHC
Within the group of B-cell NHL, it was possible to reach
an accurate final diagnosis by FCI in 31/34 B-cell NHL
cases representing 91.2% concordance. FCI showed 100%
concordance with histopathology/IHC in diagnosing all
cases of SLL and MCL (Fig 2). However, there was a differ-
ence in the other subtypes where FCI diagnosed 24 cases
as DLBCL instead of 23 cases by histopathology/IHC. The
extra case was proved to be FL by histopathology. Also, 2
cases were diagnosed as FL by FCI instead of 3 cases by
IHC representing 66.7% concordance, and 1 case was
diagnosed as TCRBCL by FCI instead of 3 cases by IHC
representing 33.3% concordance. Within the group of T-
cell NHL, there was 66.6% concordance between FCI and
IHC (one case was diagnosed as PTCL and one case was
diagnosed as ALTCL by both FCI and IHC, Fig. 3). How-
ever, one case was diagnosed as PTCL by FCI and was
proved to be ALTCL by IHC.
Statistical evaluation of FCI technique
Statistical evaluation of FCI technique included calcula-
tion of sensitivity, specificity, positive predictive value and
negative predictive value. These calculations were per-
formed to evaluate the application of FCI in diagnosis and
characterization of NHL, HL, RH and NLT. Within the
group of NHL the estimated sensitivity and specificity of
FCI were 94.6% and 100%; respectively. The positive pre-
dictive value for diagnosis of NHL by FCI was 1 and the
negative predictive value was 0.87. Within the group of
HL, the sensitivity of FCI was 40% only (2 out of 5 HL
cases were identified by FCI). However, the specificity was
100%. The positive predictive value was 1 and the nega-
tive predictive value was 0.94. Within the group of RH, the
estimated sensitivity was 100% and the specificity was
lower (89.1%). Positive predictive value was 0.44 and the
negative predictive value was 1. As for the NLT, both sen-
sitivity and specificity were 100%. Similarly, both positive
predictive and negative predictive values were 1.
From the above results, FCI technique is 100% reliable in
identifying NHL, HL and non-lymphomatous tumors as it
gave no false positive results (specific) and to a lesser
extent (89.1%) in diagnosing reactive hyperplasia. InDiagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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(A):Touch imprint of ALTCL case showing large atypical lymphoid cells with vesicular nuclei and prominent nucleoli (modified  PAP, 400 ×), (B): ALTCL case showing Diffuse infiltration by large atypical lymphoid cells with horse-shoe nuclei and prominent  nucleoli Figure 3
(A):Touch imprint of ALTCL case showing large atypical lymphoid cells with vesicular nuclei and prominent 
nucleoli (modified PAP, 400 ×), (B): ALTCL case showing Diffuse infiltration by large atypical lymphoid cells 
with horse-shoe nuclei and prominent nucleoli. Binucleated RS-like cells are encountered (arrow) (H & E, 400 ×)., (C) 
Malignant cells show positive reaction to CD 3, (D) Large anaplastic cells are positive for CD 30, (E): FCM dot plots of a case 
of ALTCL showing (i) Large FSc (ii) Negative isotype control (iii, iv) Atypical population showing positive reaction to CD45, 
CD 3, (v) Some of the CD45RO positive cells (T-cells)are positive for CD30 (vi) Positive cells for CD 30 have large FSc.
(B)    (A)   
(D)    (C )   
(E)  
  (a)
(b)
(c )  
(d)  
(e) (f)Diagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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addition, FCI technique is 100% reliable in excluding the
diagnosis of reactive hyperplasia and non-lymphomatous
tumors as it gave no false negative results (sensitive) and
to a lesser extent (94.6%) in excluding NHL. However,
FCI technique is not reliable in excluding the diagnosis of
HL as its sensitivity is only 40%. This could be attributed
to the small number of studied HL cases.
Discussion
FCI has been applied in the diagnosis of lymphoma in
lymph node biopsies as well as in extra-nodal sites. How-
ever, it requires fresh specimens to maintain viability and
avoid loss of antigenicity through the process of fixation.
So, processing of fresh tissue within minutes or few hours
is mandatory [5].
In the present study we investigated the role of FCM in tis-
sue diagnosis and classification of lymphoma. The results
of the study showed 88% concordance between FCI aided
by touch imprints and histopathology/IHC in the diagno-
sis of lymphoma. The diagnostic categories were NHL,
HL, NLT and RH. Our results are consistent with Manda-
cova et al. [24] who found a concordance between FCI
and histopathology in 89% of cases suspected to be lym-
phoma and Martinez et al. [25] who demonstrated that
218 out of 250 lymphoma cases (87.2%) were success-
fully diagnosed by FCI. A slightly higher concordance rate
(94.1%) was reported by and Dunphy [5] who stated that
FCI data were consistent with histopathologic diagnosis
of 373 lymph node specimens examined.
A slightly lower percentage of concordance was estimated
by Dong et al. [26] who assessed the ability of FCM to
diagnose and sub-classify lymphoma in 139 cases and
found that it was successful in 75% of the cases.
The role of FCI in diagnosing bone marrow infiltration by
B-cell NHL was also assessed. Carulli et al. [27] reported
that 89.5% of 114 cases studied were concordant in both
FCI and histopathologic examination.
In the present work, we used a large panel of markers
which resembles the panels utilized by other investigators
[11,25,26,28]. It is also consistent with the panel estab-
Frequency distribution histogram showing correlation  between diagnostic groups in FCI and histopathology Figure 4
Frequency distribution histogram showing correla-
tion between diagnostic groups in FCI and histopa-
thology.
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Table 2: Correlation between NHL sub-typing as characterized and diagnosed by FCI, routine histology and immunohistochemistry
B-cell lymphoma subtypes FCM diagnosed cases Histopathology & Immunohistochemistry No. (%)
Diffuse large B-cell lymphoma 24 (75) 23 (61.8)
Follicular lymphoma 2 (6.25) 3 (8.8)
Small lymphocytic lymphoma 3 (9.38) 2 (5.9)
Mantle cell lymphoma 2 (6.25) 3 (8.8)
T-cell rich B-cell lymphoma 1 (3.12) 3 (8.8)
Total 32(100) 34 (100)
T-cell lymphoma subtypes
Peripheral T-cell lymphoma 2 (66.7) 1 (33.3)
Anaplastic large T-cell lymphoma 1 (33.3) 2 (66.7)
Total 3 (100) 3 (100)Diagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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lished by the clinical cytometry society with the exception
of the additional use of CD2 and CD7 for aberrant T-cell
expression [10]. The large number of markers used in the
present study was compromised by using dual and triple
markers that detect simultaneous expression of 2 or 3
antigens on the same cell leading to a decrease in the
number and quantity of used reagents and hence decrease
in the cost/benefit value of the test.
In the present work, the studied cases were categorized
into 7 groups (A-G) based on the results of FCI and his-
topathology/IHC. In the first group (A), FCI revealed
100% concordance with IHC in the sub-typing of all FCM-
diagnosed B-cell lymphoma cases (32 cases) except for a
single case which was diagnosed as DLBCL by FCI and was
FL by histopathology although this case showed medium
to large FSc denoting a large cell size By FCM and IHC was
inconclusive for CD10 and negative for BCL-2.
In the second group, 3 cases were diagnosed as T-cell NHL
by both FCI and IHC. These results were consistent with
those of Chung et al. [29] who illustrated that T-cell sur-
face markers are predominantly expressed in all T-cell
lymphomas upon FCM analysis. However, Mayall et al.
[28] mentioned that FCI is not helpful in the diagnosis of
T-cell lymphoma since the CD4/CD8 ratio is not usually
restricted in T cell lymphomas and loss of pan-T cell anti-
gens was seen in some T-cell lymphomas. In their study, 4
out of 6 cases of T-cell lymphomas were successfully diag-
nosed by FCI whereas sub-typing was different in one case
which was diagnosed as PTCL by FCI and ALTCL by IHC
as it showed positive immunostaining for CD30. In FCI,
this case was negative for CD30. However, this contro-
versy in a single case can not be evaluated statistically due
to small number of cases. Moreover, Jones et al. [30] dem-
onstrated that CD30 is not expressed in 2% of ALTCL lym-
phoma cases.
In the third group 2 cases were successfully diagnosed as
HL by both FCI and IHC whereas in the fourth group 3
cases were diagnosed as reactive hyperplasia by FCI and as
HL, mixed cellularity type by histopathology. This could
be attributed either to an error in the gating technique
since the RS cells are CD45- and the chosen gate was
adjusted to select CD45+ve cells only or due to loss of the
large, fragile CD15+ cells during processing. Also touch
imprint didn't show RS-like cells. The same results were
reported by Witzig et al. [31] and Segal et al. [32] who also
illustrated that the large neoplastic cells are fragile and are
therefore lost during mechanical dispersion and prepara-
tion of the samples. In addition, Braylan [9] mentioned
that the neoplastic cells in HL might escape detection by
FCM due to their focal distribution in the lymph node.
In this regard, Young et al. [12] studied 107 FNA of sus-
pected lymphoid lesions by cytology and FCM. Three out
of these cases were HL but none of them showed RS cells
in the FNA samples. On the other hand, FCI of these 3
cases showed polyclonal populations and they were diag-
nosed as RH. Similarly, Mayall et al. [28] and Dong et al.
[26] provided evidence that FCI is not helpful in diagnos-
ing HL since they identified HL by FCI in 33.3% only of
cases and 44% (7 out of 16 HL cases) respectively. These
data were confirmed by The Clinical Practice Guidelines
for the Diagnosis and Management of Lymphoma which
was approved by the National health and medical
research council in Australia in 2005. According to these
guidelines FCM findings are non-contributory in HL
because the neoplastic cell population is scanty (1% of the
total number of cells in suspension) and the neoplastic RS
cells are CD45 negative.
In the fifth group, there was 100% concordance between
FCI and histopathology/IHC results in non-lymphoma-
tous tumors (4/4 cases). However, the exact typing of
these tumors by FCM was not possible as it requires addi-
tional markers which were not used in this study. These
results confirm the previously published data in this
regard [12,15,16,28,33,19]. Similarly the sixth group
showed a 100% concordance (4/4 cases) between FCI and
histopathology/IH in the diagnosis of benign lymphoid
lesions however the exact varieties of these lesions could
not be categorized by FCI. Our results in this regard are in
agreement with Jeffers et al. [34] who reported that 4 cases
were diagnosed as RH by combining data from FNAC and
FCI. Two cases were histopathologically diagnosed as RH
and the other two cases were defined as Kikuchi's disease.
Similarly, Laane et al. [35] demonstrated that 97% of 172
cases of reactive hyperplasia showed concordance
between FCI was concordant with the morphologic diag-
nosis. However, Dunphy [16] mentioned that in hyper-
plastic disorders the classic morphologic criteria are
considered more useful in the differential diagnosis.
In the current study 2 cases (4%) of pathologically-con-
firmed NHL were diagnosed as RH by FCM. Both cases
were TCRBCL and the reason for the discordance was the
presence of numerous mature T-cells and failure to detect
the monoclonal B-cells population. This is consistant with
the results of both Morse et al. [15] and Jeffers et al. [34].
Mayall et al. [28] showed that only 2 out of 73 cases were
confusing because the cytology showed a malignant
tumor with highly atypical cells mixed with benign look-
ing lymphoid cells and the FCI showed no evidence of
light chain restriction. However, paraffin embedded sec-
tions and immunohistochemistry showed that the largeDiagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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highly atypical cells were positive for CD45 and CD20
and negative for cytokeratin, S100, and CD3. Thus, a diag-
nosis of T-cell rich B-cell lymphoma was made. They
assumed that the neoplastic B-cells were not strongly
expressing light chains or they were masked by a popula-
tion of reactive B-cells.
In this research, B-cell monoclonality was detected by FCI
in 100% of FCM-diagnosed B-NHL however, these were
not assessed by IHC. It has been reported that IHC does
not usually provide a clear evidence of surface LCR due to
the large amount of background immunoglobulin in the
interstitial spaces of tissues which obscures the relatively
weak monoclonal immunoglobulins on the surface of B-
cells. The cell isolation and washing; usually required for
FCM analysis; allows unambiguous assessment of light
chain expression [19,34]. Similarly, Martinez et al. [25]
showed that LCR was successfully detected in 90.5% of B-
cell lymphoma cases (91 cases) whereas it was evaluated
in 41.8% of the cases only by IHC.
In addition, Wu et al. [36] demonstrated that Ig light
chain restriction was successfully detected by FCM in 15 of
17 88% of cutaneous B-cell lymphoma (primary or sec-
ondary), compared to 37% only by IHC. This was attrib-
uted to the fact nearly one-third of these cases were
histologically suspicious but difficult lesions due to
processing artifact, mixed cellular infiltrate, or paucity of
abnormal cells. Moreover, Gomyo et al. [37] reported that
FCI determined monoclonal B-cell population in 14 out
of 92 (15.2%) bone marrow biobsies which were consid-
ered as negative samples by morphological examination.
In the present study, the estimated sensetivity and specifi-
city of FCI in diagnosing NHL were 94.9% and 100%;
respectively whereas the positive predictive value was 1
and the negative predictive value was 0.87. Comparable
estimates were reported previously [26,25,38]. Das, [39]
denoted that combined morphology & FCI has a sensitiv-
ity & specificity of 100%
Although recent studies demonstrated the significance of
using modern techniques such as immunohistochemistry
with tissue microarray [40], c-DNA microarray [41] and
molecular pathology [42] in the proper diagnosis of lym-
phoma as well as in the prediction of patient's outcome.
The use of FCM has the advantage of quick multiparamet-
ric analysis of a very large number of cells (20.000–
50.000) cells and a better statistical representation of the
population of interest. The choice of the appropriate anti-
body combinations, gating strategy and multiparametric
analysis plays a key role in diagnosis of lymphoma [22].
FCM analysis offers another advantage over other tech-
niques, where dual and tripple markers could be applied
to detect co-expression of 2 or 3 antigens respectively on
the same cell [43].
Also, FCM has the ability of precise detection of immu-
noglobulin light chain expression and so assessing the
monoclonality of lymphoid populations [7,44].
FCI has been applied in the diagnosis of lymphoma in
lymph node biopsies as well as in extranodal sites. How-
ever, it requires fresh specimens to maintain viability and
avoid loss of antigenicity through tissue fixation, immedi-
ate suspension in chilled nutritional medium after surgi-
cal excision followed by processing of fresh tissue within
minutes or few hours [5].
On the other hand, Immunohistochemistry on paraffin-
embedded tissue is limited by poor antigen preservation
and difficulties in defining antigens restricted to cell sur-
faces, being lost through fixation, which include the
majority of lymphoid markers. Sufficient antibodies have
been developed for the identification of B- and T-cell pop-
ulations on paraffin-embedded tissue. Yet, immunoglob-
ulin light chains are not reliably demonstrated on cell
surfaces by this method [5].
It has been reported that IHC does not usually provide a
clear evidence of surface light chain restriction due to the
large amount of background immunoglobulin in the
interstitial spaces of tissues which obscures the relatively
weak monoclonal immunoglobulins on the surface of B-
cells. The cell isolation and washing; usually required for
FCM analysis; allows unambiguous assessment of light
chain expression [19,35].
FCM is more sensitive than molecular techniques (RT-
PCR, Q-RTPCR) as it avoids the probability of sample
contamination by non neoplastic cells.
In addition, c-DNA array is rather costy and sophisticated
tedious lengthy tests which can be performed in special-
ized labs only and needs high experience, special software
system
We conclude that, the FCI contributes significantly to and
are consistent with the final tissue diagnosis in the major-
ity of our studied cases (88%). The false negative results of
FCI could be attributed to the presence of heterogeneous
populations of lymphocytes that might be present in spe-
cial situations such as partial involvement of the lym-
phoid tissue by lymphoma cells, the presence of a
follicular lymphoma with normal lymphoid cells in-
between the neoplastic follicles, or the presence of numer-
ous residual non-neoplastic lymphocytes among the neo-
plastic cells of diffuse lymphomas as in T-cell-rich B-cell
lymphoma. Thus, in highly suspicious cases IHC is stillDiagnostic Pathology 2008, 3:43 http://www.diagnosticpathology.org/content/3/1/43
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required if no FCI abnormalities were detected. However,
FCI has a definite role in detection of monoclonality
(light chain) of NHL.
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